/
/
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
Un abonnement à JoVE est nécessaire pour voir ce contenu. Connectez-vous ou commencez votre essai gratuit.
1Department of Nuclear Medicine, Nanjing First Hospital,Nanjing Medical University, 2State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College, 3Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science,National Institutes for Quantum Science and Technology, 4Department of Pharmacy, Union Hospital, Tongji Medical College,Huazhong University of Science and Technology
Chapitres
- 00:00Introduction
- 01:0968Ga Radiolabeling
- 01:58Tracer Stability Test
- 03:01Cellular Uptake Experiment
- 04:33Positron Emission Tomography (PET) Imaging
- 05:50Ex Vivo Biodistribution
- 06:42Results: Analyzing In Vivo Binding Affinity, Stability, and Imaging Capacity of [68Ga]DPA
- 08:38Conclusion
This study developed a noninvasive and real-time method to evaluate the distribution of programmed death-ligand 1 in the whole body, based on positron emission tomographic imaging of [68Ga] D-dodecapeptide antagonist. This technique has advantages over conventional immunohistochemistry and improves the efficiency of identifying appropriate patients who will benefit from immune checkpoint blockade therapy.
